AGENUS INC Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
AGENUS INC (AGEN) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2012-03-06
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2011-12-31 was $0.00.
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2011-09-30 was $0.00.
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2010-12-31 was $0.00.
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2010-09-30 was $0.00.
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2011 was $0.00, a 100.00% decline from fiscal 2010.
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2010 was $629.38K.
- AGENUS INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2009 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $0.00 derived: sum of 2 quarters · filed 2012-03-06 | $0.00 10-K · filed 2012-03-06 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $0.00 10-Q · filed 2011-11-04 | ||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-05 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $0.00 derived: sum of 2 quarters · filed 2012-03-06 | $629.38K 10-K · filed 2012-03-06 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $629.38K 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $629.38K 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |